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SUPPLEMENTARY FIGURES AND TABLES
Supplementary Figure S1: Representative images of tumours classified as a proportion of tumour (PoT) of <40%, 40-
70% and >70%. A. Adenocarcinoma classified as <40% tumour (exact PoT: 24.8%). B. Adenocarcinoma classified as 40%-70% tumour 
(exact PoT: 59.2%). C. Adenocarcinoma classified as >70% tumour (exact PoT: 89.6%)
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Supplementary Figure S2: Boxplot demonstrating the median, interquartile range and range of the proportion of 
tumour among patients with and without evidence of tumour regression (Mandard tumour regression grades 1-3 and 
4-5, respectively).
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Supplementary Figure S3: Illustration of the point counting method. A. Selection of a biopsy piece with tumour. B. Outlining 
of the area of interest using a pen tool (green line). C and D. A grid with 600 equidistant measurement points generated using Randomspot 
software is superimposed onto the tissue section. The observer inspects all measurement points (tip of the arrow) manually and classifies 
the tissue type at this location.
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Supplementary Figure S4: Relationship between treatment arm and overall survival by proportion of tumour (study 
cohort divided into 5 equally sized groups (quintiles). A. biopsy proportion of tumour ≤41.86%: no significant difference in overall 
survival between treatment arms, HR (95% confidence interval): 1.31 (0.74, 2.33), p=0.3602. B. biopsy proportion of tumour between 
41.86% and 51.39%: no significant difference in overall survival between treatment arms, HR (95% confidence interval): 1.29 (0.73, 2.27), 
p=0.3803. C. biopsy proportion of tumour between 51.39% and 59.73%: patients treated with neoadjuvant combination therapy followed 
by surgery survive significantly longer than those treated by surgery alone, HR (95% confidence interval): 2.64 (1.44, 4.84), p=0.0011. 
D. biopsy proportion of tumour between 59.73% and 69.38%: patients treated with neoadjuvant combination therapy followed by surgery 
survive significantly longer than those treated by surgery alone, HR (95% confidence interval):1.87 (1.00, 3.49), p=0.0457. E. biopsy 
proportion of tumour >69.38%: no significant difference in overall survival between treatment arms, HR (95% confidence interval): 0.73 
(0.41, 1.27), p=0.2573.
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Supplementary Figure S5: The change in treatment effect according to the proportion of tumour. The central line 
represents the estimate of the log-hazard ratio, whilst the shaded area represents the 95% confidence interval around the estimate. The 
log-hazard value of 0 is equivalent to a hazard ratio of 1 (no difference between the treatment arms). Values above zero indicate a positive 
effect of chemotherapy on survival.
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Supplementary Table S1: Comparison of baseline patient characteristics of the OE02 study cohort with the whole 
OE02 trial cohort
Study cohort
(N=281)
OE02 trial cohort (N=802)
Age (years) Median 62 63
IQR 54 – 69 55 – 68
Range 30 – 83 30 – 84
n (%) n (%)
Sex Male 213 (76) 603 (75)
Female 68 (24) 199 (25)
Tumour site Upper third 3 (1) 7 (1)
Middle third 66 (23) 199 (25)
Lower third 191 (68) 514 (64)
Cardia 21 (7) 82 (10)
Histology type Adenocarcinoma 195 (69) 533 (66)
Squamous cell caricnoma 84 (30) 247 (31)
Other 2 (1) 21 (3)
*Degree of dysphagia 0 41 (15) 108 (14)
1 109 (41) 318 (42)
2 80 (30) 234 (31)
3 32 (12) 86 (11)
4 3 (1) 8 (1)
missing data 16 48
WHO performance status 0 188 (67) 532 (66)
1 82 (29) 247 (31)
2 10 (4) 21 (3)
3 1 (0) 1 (<1)
4 0 1 (<1)
Abbreviations: CS: patients treated with chemotherapy followed by surgery;IQR: interquartile range; S: patients treated 
with surgery alone; WHO: World Health Organisation.
* as described in the original trial publication: Medical Research Council Oesophageal Cancer Working Party. Surgical 
resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002; 
359(9319): 1727-33.
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Supplementary Table S2: Comparison of baseline patient characteristics of the OE02 study cohort between 
proportion of tumour groups
Study cohort
(N=281)
PoT <40%
(N=46)
PoT 40-70%
(N=183)
PoT >70%
(N=52)
Age (years) Median 62 62 62 64.5
IQR 54 – 69 56 – 70 53 – 68 57 – 69
Range 30 – 83 36 – 83 30 – 80 44 – 77
n (%) n (%) n (%) n (%)
Sex Male 213 (76) 36 (78) 139 (76) 38 (73)
Female 68 (24) 10 (22) 44 (24) 14 (27)
Tumour site Upper third 3 (1) 1 (2) 2 (1) 0 (0)
Middle third 66 (23) 8 (17) 42 (23) 16 (31)
Lower third 191 (68) 36 (78) 122 (67) 33 (63)
Cardia 21 (7) 1 (2) 17 (9) 3 (6)
Histology Adeno 195 (69) 38 (83) 129 (70) 28 (54)
Squamous 84 (30) 7 (15) 53 (29) 24 (46)
Other 2 (1) 1 (2) 1 (1) 0 (0)
*Degree of dysphagia 0 41 (15) 6 (14) 30 (17) 5 (10)
1 109 (41) 12 (28) 74 (43) 23 (48)
2 80 (30) 15 (35) 49 (28) 16 (33)
3 32 (12) 10 (23) 19 (11) 3 (6)
4 3 (1) 0 (0) 2 (1) 1 (2)
Data unavailable 16 3 9 4
WHO performance 
status
0 188 (67) 27 (59) 127 (69) 34 (65)
1 82 (29) 15 (33) 52 (28) 15 (29)
2 10 (4) 3 (7) 4 (2) 3 (6)
3 1 (0) 1 (2) 0 (0) 0 (0)
4 0 0 (0) 0 (0) 0 (0)
Abbreviations: PoT: Proportion of tumour; IQR: interquartile range; WHO: World Health Organisation. * The degree of 
dysphagia was classified as 0: Able to swallow all solids without difficulty, 1: Difficulty with swallowing some hard solids 
or particular foods, 2: Able to swallow a semi-solid or liquid diet only, 3: Able to swallow a liquid diet only and 4: Unable 
to swallow liquids or saliva
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Supplementary Table 3: Relationship of proportion of tumour group and overall survival by treatment arm (patients 
with adenocarcinoma only)
Pre-op chemotherapy followed by surgery Surgery alone
PoT <40% PoT
40% - 70%
PoT >70% PoT <40% PoT
40% - 70%
PoT 
>70%
Patients (N) 24 61 13 14 68 15
Events (N) 18 46 13 14 61 12
Median survival 
(years)
1·03 1·91 1·20 1·21 1·10 1·78
Log-rank
P-value 0·0510 0·2134
HR REF 0·76 1·61 REF 0·75 0·49
HR
P-value 0·323 0·193 0·345 0·083
Abbreviations: HR: hazard ratio; PoT: proportion of tumour
